Loading…
SERA
SERA Prognostics Inc
NASDAQ· Healthcare· Medical Devices· CUSIP 81749D107
$2.07+1.97%Price as of Aug 29, 18:37 UTC · updated once a day, after the close
Key metrics
- Market cap
- $81.66M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.66
- ROE
- -45.03%
- Profit margin
- 0.00%
- Revenue growth
- +76.50%
- Beta
- 0.98
- 52-week high
- $3.95
- 52-week low
- $1.56
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -80.3% over 5Y.
today you would have $183.62▼ -81.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $2.95 | $8.14 | $5.98 | $1.26 | $6.87 | |
| P/S | 1257.0x | 1735.8x | 3505.2x | 609.7x | 145.5x | 1257.0x |
| P/B | 1.9x | 1.9x | 5.6x | 2.7x | 0.4x | 0.7x |
| EPS | -$0.67 | -$0.99 | -$1.16 | -$1.43 | -$2.33 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ATHEAlterity Therapeutics Ltd | $4.51 | — | 0.0x | — | -47.02% | $81.75M |
| ZYBTZhengye Biotechnology Holding Ltd | $1.73 | — | 2.2x | — | -25.17% | $81.99M |
| CTORCitius Oncology Inc | $0.78 | — | 2.0x | — | -126.58% | $82.03M |
| MAIAMAIA Biotechnology, Inc. | $1.33 |
About the company
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
- 71
- Salt Lake City, United States
Company description provided by Yahoo Finance.